Apr 2026
FDA Pulled TB-500's "Risk" Flag
removed from the Category 2 danger list; nominators withdrew, PCAC review set for July 2026
1,700+
Humans Dosed With Real Tβ4
across Phase 2/3 eye & skin trials in the US, Italy, and Poland
3
Countries Co-Funding Human Trials
US, South Korea (HLB Therapeutics), China (Lee's Pharmaceuticals) — not just Washington's call
0
Human Trials for the Injury Use
the muscle/tendon/joint use it's sold for has never been tested in people — anywhere, yet
The single most important thing to understand before anything else: "TB-500" returns zero results on PubMed. Every real study is filed under its parent molecule, thymosin β-4 (Tβ4) — and the human trials that exist are for the eye and skin, run internationally, not for the muscle/tendon/joint use TB-500 is actually sold for.
THYMOSIN β-4 — the trial drug
Real human data
Full-length natural peptide. Phase 2/3 human trials for dry eye, corneal healing, and venous ulcers — run in the US, Italy, and Poland, with Asian co-development partners. Well-tolerated at trial doses.
"TB-500" — the gray-market vial
Preclinical + real-world use
Usually a short synthetic fragment of Tβ4 (the actin-binding piece), originally developed for horses. Strong animal/mechanistic case for injury recovery — zero human injury trials, because nobody with money has run one.
Eye (Dry Eye, Cornea)
Phase 2/3 human RCTs, US + Korea-funded
Skin (Venous Ulcers)
Phase 2 human RCT, run in Italy & Poland
Heart & Vascular Repair
Striking results in Hungarian, Chinese & US labs — mice and cell models
Muscle / Tendon / Injury
TB-500's actual selling point — no human trial exists anywhere yet
According to PubMed, thymosin β-4 is a natural 43-amino-acid peptide your own platelets and immune cells release after an injury. Its biology is well characterized by the scientist who discovered it, Dr. Allan Goldstein (George Washington University) — the question is whether the gray-market fragment reproduces it.
Moves Repair Cells (Actin-Binding)
Cell Migration
Tβ4's core trick: it binds actin and mobilizes stem/progenitor cells to the injury site so they can rebuild tissue — the mechanism behind every healing claim.
Builds Blood Vessels
Angiogenesis
Promotes new blood-vessel growth to feed healing tissue — the same property behind a legitimate theoretical caution for anyone with active cancer (see Safety).
Calms & De-Scars
Anti-Fibrotic
Reduces inflammation and myofibroblast count — meaning less scar tissue. This is the most compelling part of the preclinical story, and it's why cardiac labs in three countries are chasing it.
Thymosin β-4's human trials weren't confined to America — they ran across three continents. Read the "Where / Who Funded" column carefully: the international footprint is the real story most sellers and most critics both skip.
| Condition / Trial | Where / Who Funded | Scale | Result |
|---|
Neurotrophic keratopathy (non-healing corneal wounds) | US + South Korea (HLB Therapeutics / ReGenTree JV) | 1,700+ dosed program-wide | 60% complete healing vs 12.5% placebo |
Severe / moderate dry eye disease | US sites; ReGenTree/HLB (Korea) + Lee's Pharmaceuticals (China) licensed for Asia | ~80 in the two Phase 2s | Phase 2 positive; Phase 3 primary endpoints narrowly missed |
Venous (leg) stasis ulcers | Run entirely in Italy & Poland — 8 European sites, zero US sites | 73 patients | ~25% fully healed in 3 months, safety like placebo |
Heart attack & vascular repair | University of Pécs (Hungary), UT Southwestern/UCSF (US), Tongji University (Shanghai, China) | Animal + cell models | Striking preclinical results, not yet human |
Muscle, tendon, ligament & joint injury — the TB-500 use | No country has funded a human trial for this use — TB-500 was developed for racehorses | Animal + horse + testimony | No human trial anywhere — not "doesn't work," just never tested |
Follow the money — the actual reason there's a gap. Thymosin β-4's eye/skin trials got funded because RegeneRx partnered with drug companies who could patent and sell a formulation (HLB Therapeutics/ReGenTree in Korea, Lee's Pharmaceuticals in China). The injury-recovery use has no equivalent sponsor: TB-500 is an off-patent fragment nobody owns, horse-medicine-turned-biohacker-supply, sold for $30-120 a vial. There's no company that profits from proving it works for tendons, so no one has paid for that trial — in any country. "No human data" here means "no one funded the study," not "it failed a study."
The most talked-about peptide combo in the injury-recovery world — two repair peptides stacked together, nicknamed after the Marvel character who heals from anything.
BPC-157 — "the roads"
Vessels + Collagen
Builds new blood vessels and ramps up growth-factor signaling and collagen at the injury site — creating the conditions for repair. See our
full BPC-157 infographic.
TB-500 — "the crew"
Cell Migration
Mobilizes and migrates the repair cells to the site and tamps down inflammation, so the cells doing the actual rebuilding can get there.
The honest read: the mechanisms genuinely are complementary, and the real-world track record among lifters and athletes is loud and consistently positive. There is no human trial of the combination — a fact critics use to dismiss it and boosters ignore. Both are true: it's a reasonable, mechanistically sound hypothesis built on two real preclinical stories, and it hasn't been tested in a controlled human trial. Both peptides are WADA-banned in every drug-tested sport.
For a stubborn tendon or joint injury — the reason people reach for TB-500 — here's how it stacks up against options with more human evidence behind them.
Most Proven
Physical Therapy
$50-150
per session
Cortisone Injection
$100-500
per shot, often covered
PRP Injection
$500-2,000
per treatment
Research Chem
TB-500 (raw vial)
$30-120
per 5mg vial, gray market
Wolverine Stack
Clinic-Supervised Cycle
$445-795
per cycle, incl. provider oversight
The US regulatory story on TB-500 is actively changing, not settled. Present all three positions — none is "the verdict."
FDA (USA) — reversing course
Off the danger list as of April 2026
In Oct 2023 the FDA placed TB-500 in Category 2 ("significant safety risk"). On April 15, 2026, the FDA removed it — the nominators withdrew their safety concerns. It now awaits a formal Pharmacy Compounding Advisory Committee review, July 23-24, 2026. Read the 2023 flag as one contested regulatory episode, not a final scientific verdict — it's being unwound in real time.
WADA / Pro Sport
Banned at all times since 2011-2012
Prohibited under S2 (peptide hormones/growth factors affecting muscle, tendon, or ligament repair), in and out of competition. The NFL, NBA, MLB, NHL, and NCAA all ban it; detection window ~30-45 days. This is the one regulatory position that hasn't wavered.
Where else in the world
Korea, China: funding the Tβ4 side
South Korea's HLB Therapeutics and China's Lee's Pharmaceuticals hold licenses and are co-funding thymosin β-4's ophthalmic development for their markets. Russia has a more permissive framework for several peptides generally. No country has fast-tracked the injury-use fragment — that gap is universal, not uniquely American caution.
Two voices worth hearing: the researcher who built the actual science, and a credentialed physician who discusses these peptides with real patients — set against the controlled literature.
Dr. Allan L. Goldstein PhD · George Washington University · discovered the thymosins
The scientist who
discovered thymosin β-4 and authored the foundational review of its biology — actin-binding, cell migration, reduced scarring. He describes the clinical applications as "ongoing and projected" trials in his own writing: promise, backed by real mechanism, not yet proof for every use. →
PMID 22074294 — Goldstein et al.
Dr. Ashley Froese MD · Board-Certified Family Medicine · Direct Primary Care
A peptide-focused physician whose channel "This Is Not Covered" has in-depth explainers on exactly these compounds, including a dedicated breakdown of TB-500, BPC-157, and the Wolverine stack. Her point: peptides aren't a single category — TB-500's research history (wound healing, cardiac repair, corneal injury) runs decades deep, and its evidence base is among the strongest of the non-FDA-approved peptides, even though the specific injury-recovery combination hasn't been trialed.
vs. PubMed: she lands where the literature does — real mechanism and real trial history for Tβ4, genuine gap for the injectable injury use. →
Dr. Froese — This Is Not Covered
Match the tone to the real data: the trialed drug was genuinely well-tolerated; the gray-market supply chain is where the real risk lives.
In the actual trials — clean
Across 1,700+ dosed patients in the eye/skin program, Tβ4 was well-tolerated with no significant adverse events at trial doses — comparable to placebo. That's a real, sizable safety signal for the molecule itself.
The theoretical cancer question
Because it drives angiogenesis and cell migration, there's a legitimate, honestly-flagged theoretical concern it could feed an existing tumor. Not demonstrated in people — but real enough that anyone with an active cancer history should talk to a doctor first.
The real risk is the supply chain
TB-500 sold as "research chemical" is unregulated — purity, sterility, and actual dose aren't verified, and DIY injection adds contamination risk. That's a sourcing problem, not evidence the molecule itself is dangerous at a clean, correct dose.
The honest risk math: the trialed molecule has a strong safety record in 1,700+ people. The unknowns are (1) whether a gray-market fragment behaves identically, (2) long-term injection safety outside the eye/skin trials, and (3) what's actually in an unregulated vial. That's a sourcing-and-unknowns risk, not a known-toxicity risk — a materially different and more favorable picture than the FDA's 2023-2026 "significant safety risk" label suggested, which the FDA itself walked back in April 2026.
The Bottom Line — In Plain English
What it is: "TB-500" is a lab-made fragment of thymosin β-4, a natural healing peptide your body already makes after an injury. Sold gray-market, developed originally for racehorses.
What's actually proven: The full peptide has real, internationally-run human trials — Italy, Poland, the US, with Korean and Chinese partners funding development — for dry eye, corneal healing, and skin ulcers. Well-tolerated in 1,700+ people.
What isn't proven, and why: The muscle/tendon/joint use people actually buy it for has zero human trials, anywhere in the world — not because it failed a test, but because it's an unpatentable off-patent fragment nobody has a financial reason to fund a trial for. That's a funding gap, not a verdict.
Where it stands with regulators right now: The FDA flagged it as a safety risk in 2023 and reversed that call in April 2026 — this is a live, moving regulatory story, not a closed case. WADA's ban has held steady since 2011-2012 and isn't in question.
- The real science is filed under thymosin β-4, not "TB-500" — know the difference before you read anyone's claims.
- Human trials ran in Italy, Poland, the US, and are co-funded by Korea and China — this was never a US-only story.
- The safety record in the actual trials is strong: 1,700+ people, no significant adverse events.
- The injury-recovery use (the Wolverine stack) has real mechanistic and preclinical support, zero human trials — an honest gap, not proof of failure.
- The FDA reversed its "significant risk" flag in April 2026; a formal compounding review follows in July 2026.
- Banned in all drug-tested sport since 2011-2012 — that one hasn't changed and won't.